Markets:

Overview

News

Currencies

International

Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.445 +0.195 (+15.60%)

Streaming Delayed Price Updated: 12:25 PM EDT, May 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors

July 31, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? ↗

July 21, 2024

The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.

Via The Motley Fool

Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 16, 2024

Via Benzinga

Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts ↗

June 17, 2024

Via Benzinga

Forecasting The Future: 8 Analyst Projections For Fate Therapeutics ↗

May 06, 2024

Via Benzinga

UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday ↗

July 16, 2024

Via Benzinga

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

July 02, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

June 17, 2024

Via Benzinga

Where Fate Therapeutics Stands With Analysts ↗

April 11, 2024

Via Benzinga

Evaluating Fate Therapeutics: Insights From 5 Financial Analysts ↗

March 19, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics ↗

February 27, 2024

Via Benzinga

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

June 04, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

May 29, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday ↗

May 16, 2024

Via Benzinga

Recap: Fate Therapeutics Q4 Earnings ↗

February 26, 2024

Via Benzinga

FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 09, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

May 09, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates

May 06, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

May 03, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

April 22, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 10, 2024

Via Benzinga

Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

April 03, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

April 02, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

March 19, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

March 05, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Present at Upcoming March Investor Conferences

March 01, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 27, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

February 26, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For February 26, 2024 ↗

February 26, 2024

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.